Table 1 Baseline characteristics of enrolled patients.
Characteristics | Patients (N = 96) |
|---|---|
Age, n (%) | |
≤ 60 years | 23 (24.0) |
> 60 years | 73 (76.0) |
Sex, n (%) | |
Male | 37 (38.5) |
Female | 59 (61.5) |
Ann Arbor Stage, n (%) | |
I/II | 18 (18.8) |
III/IV | 78 (81.3) |
Histological grade, n (%) | |
I/II | 57 (59.4) |
IIIA | 39 (40.6) |
B symptoms, n (%) | |
Yes | 18 (18.8) |
No | 78 (81.3) |
Bone marrow involvement, n (%) | |
Yes | 37 (38.5) |
No | 56 (58.3) |
Serum β2-MG, n (%) | |
Elevated | 32 (33.3) |
Normal | 63 (65.6) |
Serum LDH, n (%) | |
Elevated | 20 (20.8) |
Normal | 75 (78.1) |
FLIPI risk category, n (%) | |
Low-risk | 35 (36.8) |
Intermediate-risk | 26 (27.4) |
High-risk | 24 (25.3) |
FLIPI-2 risk category, n (%) | |
Low-risk | 48 (52.2) |
Intermediate-risk | 21 (22.8) |
High-risk | 23 (25.0) |
Treatment, n (%) | |
R-based regimen | 48 (50.0) |
G-based regimen | 41 (42.7) |
CHOP-like regimen | 48 (50.0) |
B-based regimen | 27 (28.1) |
Observation | 4 (4.2) |
